←
Ignacio Basagoiti7,858 posts
Ignacio Basagoiti avatar

Ignacio Basagoiti

@jbasago

Médico. Dedicado a la tecnología aplicada a la salud y la sanidad. Las personas son el centro de todo #healthcare #futurist #healthliteracy #ehealth

◷ Joined May 2009▧ 97 Photos and videos
Medtorek avatar
⟳ Ignacio Basagoiti retweeted
Medtorek@Medtorek·Oct 2

🤔¿Puede una IA evaluar a otra IA clínica? 👉En 118 consultas, 7 LLM coincidieron mejor con 5 médicos al valorar fidelidad y exhaustividad que razonamiento y seguridad. 🧐Útiles para escalar controles, no para sustituir revisión experta. ⚓️bit.ly/4APXv9k

Post attachment
Medtorek avatar
⟳ Ignacio Basagoiti retweeted
Medtorek@Medtorek·Jan 24

New Guidance on Responsible Use of AI Nueva Guía de @JAMA_current para el uso responsable de la #InteligenciaArtificial @SEMERGENap @ASaludDigital @Pilar_Villanova @ramos_casals @ConSalud_es @jaime_delbarrio @jbasago @waltercurioso

Nueva orientación de @JAMA_current : Joint Commission + CHAI proponen principios de uso responsable de #IA en salud — gobernanza, validación local, transparencia, privacidad, monitoreo continuo y mitigación de sesgos — para una adopción segura y ética. ⚓️bit.ly/49Sd0AH

Post attachment
Ignacio Basagoiti avatar
Ignacio Basagoiti@jbasago·Sep 4

Ya vamos tarde. Y cuando las organizaciones descubren que no controlan lo que ocurre en consulta, tienen miedo y prohiben. Estuvimos una década sin Internet en la consulta. Esperemos que no sea así en esta ocasión. Mucho por hacer #healthIA

La IA ya está en consulta antes que las normas: 👉en 278 profesionales de salud mental, 43,5% la usaba a diario como apoyo y 33,1% en tareas con pacientes. 🎯Adopción no equivale a seguridad: faltan gobernanza, formación y evaluación bit.ly/45XUci7 Via @jmirpub

Post attachment
Manuel Ruiz-Pablos avatar
⟳ Ignacio Basagoiti retweeted
Manuel Ruiz-Pablos@manruipa·Jun 2

‼️⚠️Please read this until the end. A widely shared article has presented a deeply misleading view of Long COVID, suggesting once again that cognitive behavioral therapy, exercise, and “mind-body” approaches may be the uncomfortable truth patients refuse to accept. This needs to be challenged. Not because the nervous system does not matter. Not because psychological support cannot help. But because confusing support with cure, physiology with psychology, and heterogeneity with “it might be in your head” is exactly how medicine has harmed post-infectious patients for decades. There are articles about Long COVID that look like science journalism, but in reality they repackage, in modern language, a very old idea: if we do not fully understand a disease, maybe the problem is in the patient’s mind. And that is not science. That is repeating history. The article begins with a striking sentence: “There isn’t a single approved pharmaceutical treatment, not even a test to verify the presence of the illness.” This may sound forceful, but it is a very misleading way of presenting the problem. The fact that there is still no drug specifically approved for Long COVID, or a single diagnostic test, does not mean that “nothing has been found.” It means that we are dealing with a heterogeneous disease, probably with several biological subgroups, and that medicine has not yet converted those findings into validated clinical tools. “No single diagnostic biomarker” is not the same as “no biology.” In just a few years, immunological, vascular, neurological, endocrine, and metabolic abnormalities have been described in subgroups of Long COVID patients: autonomic dysfunction, herpesvirus reactivations such as EBV/HHV-6, alterations in the cortisol axis, autoantibodies against GPCR receptors — including adrenergic and muscarinic receptors — persistent viral antigens, endothelial damage, muscle abnormalities after exertion, mitochondrial dysfunction, persistent inflammation, and differential immune changes. Is everything settled? No. Does that mean it is psychological? Also no. Science does not work like that. Multiple sclerosis did not stop existing before we had MRI. Many autoimmune diseases do not show up in routine blood tests. If a complete blood count, a basic biochemistry panel, or an X-ray comes back “normal, normal, normal,” that does not prove the absence of disease. It only proves that you are looking with inadequate tools. One of the article’s most serious mistakes is this: it confuses the absence of a simple clinical test with the absence of organic disease. And that mistake has caused harm for decades. The article also says: “Almost $2 billion and half a decade of international effort have yielded little more than hypotheses about micro blood clots and spike proteins and mitochondrial dysfunction.” No. That is not correct. A hypothesis is a provisional explanation. But when you compare patients and controls and find significant differences in muscle tissue, metabolism, response to exertion, immune biomarkers, viral antigens, autoantibodies, or vascular dysfunction, you are no longer talking about “little more than hypotheses.” You are talking about lines of biomedical evidence that still need to be organized, replicated, stratified, and translated into treatments. That is not scientific failure. That is research into a complex and new disease. 🔵Continued in the next post.👇🏻 (1/6)

WIRED@WIREDJun 1

Six years since the height of the pandemic, the scientific community remains baffled by long Covid. But there might finally be a way forward for long Covid treatment—if only you were allowed to talk about it. wired.com/story/the-painful-…

ITACA Institute avatar
⟳ Ignacio Basagoiti retweeted
ITACA Institute@itacaUPV·May 27

😃Last week,👨‍💻 Carlos Fernández Llatas, @SabienUPV group, delivered a workshop at the SEMERGEN- Murcia, where he explained the potential of #ProcessMining for the efficiency of healthcare systems through data and #ArtificialIntelligence. 🙌Working,caring and improving our system!

Post attachment
European Hospital avatar
⟳ Ignacio Basagoiti retweeted
European Hospital@EuropHospital·May 22

A more comprehensive system for #DrugSafety evaluation: Researchers from 🇪🇸 @SabienUPV have developed a new tool to estimate the risk of using medicines while 🚗 driving. dlvr.it/TSgJYC

Ignacio Basagoiti avatar
Ignacio Basagoiti@jbasago·May 21

Investigadores del grupo @SabienUPV de la @UPV han desarrollado una nueva herramienta que identifica con precisión el riesgo asociado al uso de #medicamentos durante la #conducción. @vtraver Salvador Borja @valenciaplaza valenciaplaza.com/valenciapl…

Asociación RUVID avatar
⟳ Ignacio Basagoiti retweeted
Asociación RUVID@asociacionruvid·May 14

🚘💊 Una nueva herramienta identifica mejor qué medicamentos pueden afectar más a la conducción tinyurl.com/2yeky58c Desarrollo liderado por Vicente Traver y Salvador Borja, investigadores @SabienUPV, que mejora la evaluación tradicional basada en el sistema DRUID.

ITACA Institute avatar
⟳ Ignacio Basagoiti retweeted
ITACA Institute@itacaUPV·May 14

👩‍🎓👨‍🎓Our @SabienUPV group has developed a new tool to estimate the risk of using medicines while driving🚗. 🙌For this reason, they propose a qualitative📈 tool that systematically integrates different variables. 🗞️News with the details here⤵️ 🔗 tinyurl.com/mpjrx6wh

0:30
ITACA Institute avatar
⟳ Ignacio Basagoiti retweeted
ITACA Institute@itacaUPV·Feb 25

👉Recently, the international study📝 led by our @SabienUPV group, appeared on regional TV @la8mediterraneo . 📺 In the interview, 👨‍🏫 @vtraver, head of the SABIEN, highlighted the impact of #AI in Neonatal Intensive Care Units and how it improves support decision-making.

2:00
Ignacio Basagoiti avatar
Ignacio Basagoiti@jbasago·Feb 25

El Hospital General de Valencia impulsa el proyecto #Anestech, pionero de evaluación preanestésica remota con #inteligenciaartificial y herramientas de ciberseguridad avanzada. Vía Valencia Plaza @SabienUPV valenciaplaza.com/valenciapl…